National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.

 

NCPE Assessment Process Complete
Rapid review commissioned 21/06/2018
Rapid review completed 17/07/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 31/07/2018